Jakarta, IDN Times – PT Merck Tbk has sanctioned the distribution of a final dividend of Rp123.2 billion, equivalent to Rp275 per share, for the fiscal year 2025. This significant decision was formally approved during the company’s Annual General Meeting of Shareholders (AGMS).
The pharmaceutical giant reported a period of remarkable growth throughout 2025, showcasing robust financial performance. Merck’s revenue experienced a substantial 16 percent increase, climbing from Rp1.04 trillion in 2024 to a impressive Rp1.2 trillion.
“This surge in revenue directly fueled a 66 percent rise in the company’s operating profit, elevating it from Rp193 billion to Rp320 billion. Concurrently, the net profit for the year escalated by 59 percent, reaching Rp244 billion, a significant jump from Rp153 billion in the previous year,” stated Evie Yulin, President Director of PT Merck Tbk, in an official statement released on Wednesday, May 27, 2026.
Underscoring the company’s strategic vision, Evie Yulin explained that Merck Tbk’s strong performance in 2025 and the first quarter of 2026 epitomizes its unwavering commitment to fostering healthy and sustainable growth. This is achieved through the continuous strengthening of its healthcare business, stringent operational discipline, and a dedicated focus on delivering broader benefits to society. She further emphasized the company’s dedication to cultivating an adaptive, resilient, and sustainably growing business, reiterating Merck’s resolve to make a lasting positive impact on the community and the entire health ecosystem in Indonesia.
Building on this robust performance, Merck Tbk’s total assets for 2025 reached Rp1.27 trillion, marking an impressive 33 percent increase compared to the previous year. Correspondingly, equity also saw a healthy rise of 21 percent, reaching Rp976 billion, largely attributed to the increase in retained earnings. Furthermore, the company recorded a substantial increase in operating cash flow throughout 2025, a testament to enhanced cash receipts from customers and consistently disciplined operational management.
Looking ahead, Merck sustained its positive momentum into the first quarter of 2026, demonstrating continued vigorous growth of approximately 32 percent compared to the same period in the prior year. This impressive expansion was spearheaded by increased sales across all business divisions, particularly within the Healthcare products segment, benefiting both key partners and export activities. Notably, in Q1 2026, diabetes products remained a cornerstone of the Healthcare business’s sales, contributing 24 percent of the total and registering a remarkable 51.1 percent growth year-over-year.
Beyond diabetes care, other product categories also reported significant advancements: fertility products grew by 18.2 percent, thyroid products by 44.9 percent, and endocrinology products by 2.4 percent. The combined effect of increased sales volume and a favorable product mix effectively propelled a 30 percent rise in gross profit compared to the corresponding period last year.
In a further testament to its operational efficiency, Merck Tbk’s operating profit for the first quarter of 2026 soared by approximately 380 percent year-on-year (yoy). This dramatic increase was primarily driven by strategic cost-saving initiatives. The company’s cash and cash equivalents also strengthened, reaching approximately Rp443 billion by the end of March 2026, bolstered by an enhanced operating cash flow.
Beyond its impressive financial figures, Merck Tbk remains deeply committed to conducting business responsibly and creating a positive societal impact. The company firmly believes that advancements in science and the pursuit of sustainable business practices must be integrated to broaden access to healthcare for a greater number of patients. Demonstrating this commitment, through various environmental sustainability initiatives in 2025, Merck successfully reduced its Scope 1 and 2 greenhouse gas (GHG) emissions by a substantial 87.5 percent compared to its 2020 baseline, remarkably surpassing its previously set 2030 target.
This significant reduction in emissions was made possible by the continuous operation of rooftop solar panels since 2024 and the strategic adoption of renewable energy sources for its operational facilities in Jakarta. Furthermore, the company is actively pursuing other key sustainability initiatives, including enhanced water use efficiency, waste management founded on the 4R principles (Reduce, Reuse, Recycle, Recover), and a dedicated greening program that involves planting 1,000 mangrove trees to support carbon emission reduction and the preservation of vital ecosystems.
Summary
PT Merck Tbk has sanctioned a final dividend of Rp123.2 billion, equivalent to Rp275 per share, for the fiscal year 2025, a decision approved during its Annual General Meeting of Shareholders. The company reported robust financial performance in 2025, with revenue increasing by 16 percent to Rp1.2 trillion. This surge led to a 66 percent rise in operating profit, reaching Rp320 billion, and a 59 percent increase in net profit to Rp244 billion, underscoring significant growth.
Merck sustained this positive momentum into the first quarter of 2026, demonstrating 32 percent growth driven by increased sales across all business divisions, particularly Healthcare products, with operating profit soaring by approximately 380 percent. Beyond financial achievements, Merck Tbk also significantly reduced its Scope 1 and 2 greenhouse gas emissions by 87.5 percent in 2025 compared to its 2020 baseline, surpassing its 2030 target through renewable energy and solar panels. The company remains committed to sustainable practices, including water efficiency and waste management.
